SCHEMBL9920430

SCHEMBL9920430

CCOC(=O)c1ncn[nH]1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.47
MEN1 O00255 2/20 0.47
KMT2A Q03164 2/20 0.47
L3MBTL1 Q9Y468 2/20 0.44
PDE4D Q08499 1/20 0.44
KDM4E B2RXH2 5/20 0.44
HPGD P15428 2/20 0.44
HTT P42858 1/20 0.44
RECQL P46063 1/20 0.44
JMJD6 Q6NYC1 1/20 0.42
CYP1A2 P05177 3/20 0.42
CYP2C19 P33261 2/20 0.42
CYP2C9 P11712 1/20 0.42
LMNA P02545 1/20 0.41
RAB9A P51151 1/20 0.41
HSD17B10 Q99714 1/20 0.41
TSHR P16473 1/20 0.41
CYP3A4 P08684 1/20 0.41
APOBEC3A P31941 1/20 0.41
APOBEC3G Q9HC16 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9252055 0.82 KDM4E (0.42) ALDH1A1MEN1KMT2AL3MBTL1KDM4E
SCHEMBL22372125 0.81 TSHR (0.46) MEN1KMT2AL3MBTL1KDM4EHPGD
SCHEMBL22372029 0.78 PHLPP2 (0.45) ALDH1A1CYP1A2CYP2C19CYP2C9LMNA
SCHEMBL30281192 0.77 KDM4E (0.43) ALDH1A1MEN1KMT2AL3MBTL1KDM4E
SCHEMBL1625704 0.77 POLB (0.50) ALDH1A1MEN1KMT2AL3MBTL1PDE4D
SCHEMBL22372222 0.76 L3MBTL1 (0.45) ALDH1A1MEN1KMT2AL3MBTL1KDM4E
SCHEMBL1430119 0.74 CYP1A2 (0.45) ALDH1A1L3MBTL1KDM4EHPGDHTT
SCHEMBL22372303 0.74 CYP1A2 (0.39) MEN1KMT2AL3MBTL1KDM4EHPGD
SCHEMBL29111666 0.71 LMNA (0.54) ALDH1A1KDM4ELMNARAB9AHSD17B10
SCHEMBL2823462 0.70 KDM4E (0.47) ALDH1A1MEN1KMT2AL3MBTL1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120149691-A1 Pyrrolo [1,2-b] Pyridazine Derivatives as Janus Kinase Inhibitors BIOCRYST PHARMACEUTICALS, INC. (US) 2012-06-14 US disclosed
US-20120149691-A1 Pyrrolo [1,2-b] Pyridazine Derivatives as Janus Kinase Inhibitors BIOCRYST PHARMACEUTICALS, INC. (US) 2012-06-14 US disclosed
WO-2011014817-A1 PYRROLO [1, 2-B] PYRIDAZINE DERIVATIVES AS JANUS KINASE INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2011-02-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120149691-A1 Pyrrolo [1,2-b] Pyridazine Derivatives as Janus Kinase Inhibitors JAK1, JAK2, JAK3 ALDH1A1 1632/4885MEN1 888/4885KMT2A 774/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.